Results 71 to 80 of about 29,324 (231)

Targeted disruption of the Kcnj5 gene in the female mouse lowers aldosterone levels. [PDF]

, 2018
Aldosterone is released from adrenal zona glomerulosa (ZG) cells and plays an important role in Na and K homoeostasis. Mutations in the human inwardly rectifying K channel CNJ type (KCNJ) 5 (KCNJ5) gene encoding the G-coupled inwardly rectifying K ...
Al Maskari, Raya, Figg, Nicola, Hardege, Iris, Long, Lu, O'Shaughnessy, Kevin M   +4 more
core   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Assessment of fenofibrate-methylation interactions on triglycerides using longitudinal family data

BMC Proceedings, 2018
Background Triglyceride (TG) concentrations decrease in response to fenofibrate treatment, and also are associated with DNA methylation. But how interactions between fenofibrate response and DNA methylation affect TGs remains unclear.
Jih-Chang Yu, Fang-Chi Hsu, Yen-Feng Chiu   +2 more
doaj   +1 more source

Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice. [PDF]

PLoS ONE, 2014
Peroxisome proliferator-activated receptor (PPAR)-α, a lipid-sensing transcriptional factor, serves an important role in lipotoxicity. We evaluated whether fenofibrate has a renoprotective effect by ameliorating lipotoxicity in the kidney. Eight-week-old
Yu Ah Hong, Ji Hee Lim, Min Young Kim, Tae Woo Kim, Yaeni Kim, Keun Suk Yang, Hoon Suk Park, Sun Ryoung Choi, Sungjin Chung, Hyung Wook Kim, Hye Won Kim, Bum Soon Choi, Yoon Sik Chang, Cheol Whee Park   +13 more
doaj   +1 more source

Potential neuroprotective and therapeutic agents and their mechanisms for irradiation‐induced brain injury

Ibrain, EarlyView.
In this review, agents such baicalein, troxerutin, epigallocatechin gallate, quercetin, melatonin, valproic acid, lithium, neurosteroid progesterone, as well as minocycline have been implicated as neuroprotective agents for irradiation‐induced neurological deficits. Also, agents such as glucocorticoids, methylphenidate, vitamin E, bisdemethoxycurcumin,
Seidu A. Richard, Vivian Kapio Abem, Sagor Kumar Roy   +2 more
wiley   +1 more source

Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy : pain relief and neuroprotection share a PPAR-alpha-mediated mechanism [PDF]

, 2013
Peer reviewedPublisher ...
Calignano, A, D'Agostino, G, Di Cesare Mannelli, L, Ghelardini, C, Pacini, A, Russo, R, Zanardelli, M   +6 more
core   +4 more sources

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, EarlyView.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential

Translational Oncology, 2019
Anticancer effects of a common lipid-lowering drug, fenofibrate, have been described in the literature for a quite some time; however, fenofibrate has not been used as a direct anticancer therapy.
J. Stalinska, E. Zimolag, NA. Pianovich, A. Zapata, A. Lassak, M. Rak, M. Dean, D. Ucar-Bilyeu, D. Wyczechowska, F. Culicchia, L. Marrero, L. Del Valle, J. Sarkaria, F. Peruzzi, BS Jursic, K. Reiss   +15 more
doaj   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 4, Page 494-506, February 2026.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invernizzi, George Mells, Emma L. Culver, Palak J. Trivedi   +18 more
wiley   +1 more source

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. [PDF]

, 2016
BackgroundExcess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels.
Girardet, Jean-Luc, Hagerty, David T, Hyndman, David, Iverson, Cory, Liu, Sha, Manhard, Kimberly, Miner, Jeffrey N, Nanavati, Payal, Quart, Barry, Shen, Zancong, Tan, Philip K, Terkeltaub, Robert, Yeh, Li-Tain   +12 more
core   +2 more sources